Status:

UNKNOWN

BIOTRONIK - BIOFLOW-III Registry French Satellite

Lead Sponsor:

Biotronik France

Conditions:

Coronary Artery Diseases

Eligibility:

All Genders

18+ years

Brief Summary

For the majority of Coronary Artery Disease (CAD) treatment with Percutaneous Transluminal Coronary Angioplasty (PTCA) provides high initial procedure success. However, the medium to long-term complic...

Eligibility Criteria

Inclusion

  • Symptomatic coronary artery disease
  • Subject has signed informed consent for data release
  • Subject is geographically stable and willing to participate at all follow up assessments
  • Subject is ≥ 18 years of age

Exclusion

  • Subject did not sign informed consent for data release
  • Pregnancy
  • Known intolerance to aspirin, clopidogrel, ticlopidine, heparin or any other anticoagulation / antiplatelet therapy required for PCI, stainless steel, Sirolimus or contrast media

Key Trial Info

Start Date :

November 19 2014

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

September 1 2021

Estimated Enrollment :

1000 Patients enrolled

Trial Details

Trial ID

NCT02273648

Start Date

November 19 2014

End Date

September 1 2021

Last Update

December 14 2017

Active Locations (50)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 13 (50 locations)

1

CH d'Aix en Provence

Aix-en-Provence, France

2

Clinique de l'Europe

Amiens, France

3

Centre Hospitalier d'Antibes

Antibes, France

4

Clinique Rhône Durance

Avignon, France

BIOTRONIK - BIOFLOW-III Registry French Satellite | DecenTrialz